vaccines

IMPACT FACTOR 5.2 | Indexed in: PubMed | CITESCORE 8.9

an Open Access Journal by MDPI

Cancer Immunotherapy and Vaccination: Mechanistic Insights into Lymphocyte-Mediated Immune Modulation

Guest Editor:

Dr. Jianmei Leavenworth
Heersink School of Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL 35233, USA

Deadline for manuscript submissions:
closed (31 December 2022)

Message from the Guest Editor

Cancer remains a major public health and economic issue with an ever-increasing burden. The advancement of cancer vaccines and immunotherapies, including checkpoint inhibitors and oncolytic virotherapy, that are able to amplify the body's immune system against cancer has shown great promise. However, many human cancers fail to respond to these regimens due to the body's own immunosuppressive tumor-promoting mechanisms that represent critical barriers to effective anti-tumor immunotherapies and vaccination. These mechanisms include the presence of immunosuppressive cells, e.g., regulatory T-cells, and dysfunctional effector cells that fail to exert anti-tumor activity in the tumor microenvironment. This Special Issue aims to provide a platform to all scientists working in these fields to discuss the currently known and any new mechanisms underlying the immune modulation induced by any developed or new cancer vaccines and immunotherapeutic approaches, with a focus on the immune responses driven by lymphocytes, including T-cells, B-cells, NK and innate lymphoid cells (ILC).

vaccines

IMPACT FACTOR 5.2 | Indexed in: PubMed | CITESCORE 8.9

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com